Curanex Pharmaceuticals (CURX) Common Equity (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Common Equity came in at $11.2 million in Q4 2025, up 2128.84% YoY from $503360.0 in Q4 2024, and down 21.5% on a QoQ basis from $14.3 million in Q3 2025.
Curanex Pharmaceuticals (CURX) Common Equity (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Common Equity data on file, last reported at $11.2 million in Q4 2025.
- Quarterly Common Equity rose 2128.84% year-over-year to $11.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.2 million (up 2128.84% YoY) and the FY2025 annual result came in at $11.2 million, up 2128.84% from the prior year.
- Common Equity slipped to $11.2 million in Q4 2025, from $14.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $14.3 million in Q3 2025 to a low of $305431.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Curanex Pharmaceuticals | 6.11 Mn | 1.11 Mn | - | 11.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.22 Mn |
| Sep 30, 2025 | 14.29 Mn |
| Jun 30, 2025 | 305,431.00 |
| Dec 31, 2024 | 503,360.00 |
| Sep 30, 2024 | 624,165.00 |